1525 Superior Avenue, Suite 200
Newport Beach, CA 92663
Phone (949) 650-0506
Fax (949) 999-8126

Receive our newsletter
  Home  
  Our Team  
  Patient Info  
  Contact Us  

News for Healthier Living

Mayo Clinic Uses Investigational Targeted Radiopharmaceutical Theranostic for Hepatocellular Carcinoma in First-in-Human Clinical Trial

Mayo Clinic recently became the first institution to administer an investigational radioactive medicine to a patient with hepatocellular carcinoma (HCC), the most common type of liver cancer. The investigational medicine is a targeted radiopharmaceutical theranostic (RPT) that is designed to target a novel protein called glypican-3 (GPC3). The RPT was administered to the patient as part of a first-in-human clinical trial for the targeted therapy. This investigational RPT includes both a diagnostic imaging agent, intended to identify the cancer cells, and a therapeutic agent, intended to target and kill cancer cells.

October 6, 2025


October 12 2025

October 11 2025

October 10 2025

October 9 2025

October 8 2025

October 7 2025

October 6 2025

October 5 2025

October 4 2025

October 3 2025

October 2 2025

October 1 2025

September 30 2025

September 29 2025

September 28 2025